• V. V. Petrushenko
  • D. I. Grebeniuk
  • N. A. Liakhovchenko
  • O. V. Levadnyi
  • A. S. Cheshenchuk
Keywords: phosphatidylcholine; liver cirrhosis; esophageal and gastric variceal bleeding; quality of life.


Summary. The aim of the study was to evaluate the dynamics of changes in the quality of life of patients with liver cirrhosis complicated by esophageal and gastric variceal bleeding while taking phosphatidylcholine.

Materials and methods. 62 patients with a confirmed diagnosis of liver cirrhosis complicated by esophageal and gastric variceal bleeding were included in the study. Patients were divided into two groups – main group (32 patients, standard therapy, supplemented with phosphatidylcholine) and comparison group (30 patients, standard therapy). The quality of life was assessed by syndrome on days 1st-2nd, 7th and 30th.

Results. The intensity of the studied syndromes at the beginning of the study did not differ significantly in both groups. In patients of the main group, there was a tendency to a more rapid progressive decrease in the intensity of the studied parameters both during their stay in the hospital and after discharge. The improvement in the quality of life after the discharge of patients of main group from the hospital is associated with the continuation of the course of taking the capsule form of phosphatidylcholine.

Conclusions. Prescribing of phosphatidylcholine to patients with liver cirrhosis complicated by esophageal and gastric variceal bleeding can significantly improve the quality of life.


1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8. Erratum in: Lancet. 2019 Jun 22;393(10190):e44. Erratum in: Lancet. 2018 Nov 17;392(10160):2170. PMID: 30496103; PMCID: PMC6227606.
2. Berumen J, Baglieri J, Kisseleva T, Mekeel K. Liver fibrosis: Pathophysiology and clinical implications. Wiley Interdiscip Rev Syst Biol Med. 2021 Jan;13(1):e1499. doi: 10.1002/wsbm.1499. Epub 2020 Jul 26. PMID: 32713091.
3. Fleming KM, Aithal GP, Card TR, West J. The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Aliment Pharmacol Ther. 2010 Dec;32(11-12):1343-50. doi: 10.1111/j.1365- 2036.2010.04473.x. Epub 2010 Oct 4. PMID: 21050236.
4. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9. doi: 10.1053/j. gastro.2013.02.042. Epub 2013 Mar 6. PMID: 23474284.
5. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006 Jan;44(1):217-31. doi: 10.1016/j.jhep.2005.10.013. Epub 2005 Nov 9. PMID: 16298014.
6. Fleming KM, Aithal GP, Card TR, West J. All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver Int. 2012 Jan;32(1):79-84. doi: 10.1111/j.1478-3231.2011.02517.x. Epub 2011 Apr 6. PMID: 21745279.
7. Ge PS, Runyon BA. Treatment of Patients with Cirrhosis. N Engl J Med. 2016 Aug 25;375(8):767-77. doi: 10.1056/ NEJMra1504367. PMID: 27557303.
8. Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova EN, Vovk EI, Starostin KM. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia. BMJ Open Gastroenterol. 2020 Mar 26;7(1):e000368. doi: 10.1136/bmjgast-2019-000368. PMID: 32337059; PMCID: PMC7170405.
9. Chen M, Huang H, Zhou P, Zhang J, Dai Y, Yang D, Fan X, Pan H. Oral Phosphatidylcholine Improves Intestinal Barrier Function in Drug-Induced Liver Injury in Rats. Gastroenterol Res Pract. 2019 Sep 2;2019:8723460. doi: 10.1155/2019/8723460. PMID: 31565053; PMCID: PMC6745161.
10. Gundermann KJ, Kuenker A, Kuntz E, Droździk M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011;63(3):643-59. doi: 10.1016/s1734-1140(11)70576-x. PMID: 21857075.
How to Cite
Petrushenko, V. V., Grebeniuk, D. I., Liakhovchenko, N. A., Levadnyi, O. V., & Cheshenchuk, A. S. (2021). EFFECT OF PHOSPHATIDYLCHOLINE ON THE QUALITY OF LIFE IN PATIENTS WITH ESOPHAGEAL AND GASTRIC VARICEAL BLEEDING . Kharkiv Surgical School, (3), 16-20. https://doi.org/10.37699/2308-7005.3.2021.04